Health Care & Life Sciences » Pharmaceuticals | Spring Bank Pharmaceuticals Inc.

Spring Bank Pharmaceuticals Inc. | Mutual Funds

Mutual Funds that own Spring Bank Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
AXA Framlington Biotech Fund
263,880
2%
50,570
0.53%
02/28/2018
iShares Russell 2000 ETF
232,470
1.76%
-123
0.01%
09/06/2018
Vanguard Total Stock Market Index Fund
225,402
1.71%
0
0%
07/31/2018
131,656
1%
0
0.59%
05/31/2018
Vanguard Extended Market Index Fund
119,071
0.9%
201
0%
07/31/2018
iShares Russell 2000 Growth ETF
99,514
0.76%
0
0.01%
09/06/2018
Carnegie Global Health Care Fund
70,584
0.54%
-2,188
0.55%
08/31/2018
Fidelity Spartan Extended Market Index Fund
40,920
0.31%
0
0%
07/31/2018
iShares Micro Cap ETF
30,116
0.23%
0
0.04%
09/06/2018
Schwab Small Cap Index Fund
20,800
0.16%
20,800
0.01%
06/30/2018

About Spring Bank Pharmaceuticals

View Profile
Address
35 Parkwood Drive
Hopkinton Massachusetts 01748
United States
Employees -
Website http://www.springbankpharm.com
Updated 07/08/2019
Spring Bank Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its pipeline include RIG-I & STING Agonists platforms. The company was founded by Douglas J.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.